Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says
The Federal Trade Commission and seven states have asked a federal judge to hold Martin Shkreli in contempt, alleging that he repeatedly breached his lifetime ban from the pharmaceutical industry. They say he traded shares in drug companies and used livestreams to comment on their businesses, conduct the 2022 ban explicitly prohibits.
The alleged breaches span four periods from 2022 to a trading challenge launched in June 2026 with a $10 million account. The authorities want Shkreli to sell his pharmaceutical holdings and pay a fine tied to his trading profits, with further penalties, potentially including jail, for future breaches. The ban followed his role in raising Daraprim’s price from $17.50 to $750 per pill; Shkreli denies expecting action from the Trump administration’s FTC.
- FTC and seven states allege Shkreli broke his lifetime pharma ban.
- They seek divestment, fines and clearer penalties for future breaches.
- The allegations include livestreamed stock commentary and trading.
New here? Start with this
Martin Shkreli is a former pharmaceutical executive who became widely known after his company sharply raised the price of Daraprim, a medicine used to treat a serious infection. In 2022, a federal court barred him for life from working in the pharmaceutical industry.
The Federal Trade Commission is a US government agency that enforces consumer protection and competition laws. The court order also restricts Shkreli from trading in pharmaceutical companies and commenting on their businesses, so the allegations concern whether he has complied with those limits.
The case matters because a judge’s decision could determine how the ban is enforced and what penalties apply if it was breached. The FTC’s request is supported by seven states, and Shkreli disputes the allegations.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
The authorities’ case is that a lifetime ban must be enforced consistently if it is to protect consumers and deter people from using financial influence or public commentary to affect pharmaceutical businesses. If the alleged trades and livestreams fall within the ban, requiring him to sell the holdings and imposing penalties tied to any gains could uphold the court’s order and prevent further breaches.
The case against
Shkreli could argue that contempt findings and severe penalties require clear proof that each specific trade or comment violated the ban, rather than a broad reading of its terms. He may also contend that trading shares or discussing companies does not necessarily amount to participating in the pharmaceutical industry, and that any remedy should be proportionate to proven violations and profits.